Pharmacokinetics of sepantronium bromide (YM155), a small-molecule suppressor of survivin, in Japanese patients with advanced solid tumors: dose proportionality and influence of renal impairment

Lignende værker

• Population pharmacokinetic modeling of Sepantronium bromide (YM155), a small molecule survivin suppressant, in patients with non-small cell lung cancer, hormone refractory prostate cancer, or unresectable stage III or IV melanoma
  af: Aoyama, Yumiko, et al.
  Udgivet: (2012)
• Generation of reactive oxygen species is the primary mode of action and cause of survivin suppression by sepantronium bromide (YM155)
  af: Wani, Tasaduq Hussain, et al.
  Udgivet: (2021)
• Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells
  af: Gholizadeh, Shima, et al.
  Udgivet: (2018)
• A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer
  af: Kelly, R. J., et al.
  Udgivet: (2013)
• Adaptation to chronic exposure to sepantronium bromide (YM155), a prototypical survivin suppressant is due to persistent DNA damage-response in breast cancer cells
  af: Wani, Tasaduq H., et al.
  Udgivet: (2018)